AU2019270277B9 - Treatment of cancer - Google Patents

Treatment of cancer Download PDF

Info

Publication number
AU2019270277B9
AU2019270277B9 AU2019270277A AU2019270277A AU2019270277B9 AU 2019270277 B9 AU2019270277 B9 AU 2019270277B9 AU 2019270277 A AU2019270277 A AU 2019270277A AU 2019270277 A AU2019270277 A AU 2019270277A AU 2019270277 B9 AU2019270277 B9 AU 2019270277B9
Authority
AU
Australia
Prior art keywords
ser
val
thr
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019270277A
Other languages
English (en)
Other versions
AU2019270277A1 (en
AU2019270277B2 (en
Inventor
Shaad Essa Abdullah
Ashok Kumar Gupta
Xuyang SONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
MedImmune Ltd
Original Assignee
Innate Pharma SA
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA, MedImmune Ltd filed Critical Innate Pharma SA
Publication of AU2019270277A1 publication Critical patent/AU2019270277A1/en
Application granted granted Critical
Publication of AU2019270277B2 publication Critical patent/AU2019270277B2/en
Publication of AU2019270277B9 publication Critical patent/AU2019270277B9/en
Priority to AU2025200275A priority Critical patent/AU2025200275A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019270277A 2018-05-15 2019-05-14 Treatment of cancer Active AU2019270277B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200275A AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671521P 2018-05-15 2018-05-15
US62/671,521 2018-05-15
PCT/EP2019/062305 WO2019219658A1 (en) 2018-05-15 2019-05-14 Treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200275A Division AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Publications (3)

Publication Number Publication Date
AU2019270277A1 AU2019270277A1 (en) 2021-01-07
AU2019270277B2 AU2019270277B2 (en) 2024-11-21
AU2019270277B9 true AU2019270277B9 (en) 2024-12-05

Family

ID=66752041

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019270277A Active AU2019270277B9 (en) 2018-05-15 2019-05-14 Treatment of cancer
AU2025200275A Pending AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200275A Pending AU2025200275A1 (en) 2018-05-15 2025-01-14 Treatment of cancer

Country Status (13)

Country Link
US (1) US12209126B2 (enExample)
EP (1) EP3793607A1 (enExample)
JP (2) JP7531404B2 (enExample)
KR (1) KR102885515B1 (enExample)
CN (1) CN112203691A (enExample)
AU (2) AU2019270277B9 (enExample)
CA (1) CA3099820A1 (enExample)
EA (1) EA202092696A1 (enExample)
IL (1) IL278618B2 (enExample)
MA (1) MA52627A (enExample)
SG (1) SG11202011117VA (enExample)
TW (1) TW202011989A (enExample)
WO (1) WO2019219658A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료
CN113583127A (zh) * 2020-04-30 2021-11-02 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
IL297412A (en) * 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
EP4150058A4 (en) * 2020-05-13 2024-06-19 Nanjing Legend Biotech Co., Ltd. COMPOSITIONS AND METHODS FOR REDUCING HOST REJECTION OF ALLOGENIC CELLS USING MONKEY ICP47 AND VARIANTS THEREOF
WO2023284874A1 (zh) * 2021-07-16 2023-01-19 克莱格医学有限公司 用于肿瘤免疫学的组合物和方法
CA3233771A1 (en) * 2021-10-04 2023-04-13 Les Laboratoires Servier Cancer therapy targeting nkg2a
US20240415889A1 (en) * 2021-12-14 2024-12-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd94/nkg2a heterodimer polypeptides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
MX2008015830A (es) 2006-06-30 2009-01-09 Novo Nordisk As Anticuerpos anti-nkg2a y usos de los mismos.
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
BRPI0908508A2 (pt) 2008-01-24 2016-03-22 Novo Nordisk As anticorpo monoclonal nkg2a anti-humano humanizado
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
EP3186282A1 (en) * 2014-08-28 2017-07-05 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
DK3193929T3 (da) 2014-09-16 2019-08-19 Innate Pharma Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
CN113929782B (zh) 2014-09-16 2024-06-21 依奈特制药公司 对淋巴细胞中抑制途径的中和
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
JP2019503349A (ja) * 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
RS61901B1 (sr) 2016-01-21 2021-06-30 Innate Pharma Neutralizacija inhibitornih puteva u limfocitima
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료

Also Published As

Publication number Publication date
US20210253694A1 (en) 2021-08-19
EP3793607A1 (en) 2021-03-24
IL278618B1 (en) 2025-07-01
WO2019219658A1 (en) 2019-11-21
JP7531404B2 (ja) 2024-08-09
SG11202011117VA (en) 2020-12-30
IL278618B2 (en) 2025-11-01
KR102885515B1 (ko) 2025-11-12
CN112203691A (zh) 2021-01-08
AU2019270277A1 (en) 2021-01-07
US12209126B2 (en) 2025-01-28
JP2024102055A (ja) 2024-07-30
AU2025200275A1 (en) 2025-01-30
MA52627A (fr) 2021-03-24
CA3099820A1 (en) 2019-11-21
AU2019270277B2 (en) 2024-11-21
EA202092696A1 (ru) 2021-04-05
IL278618A (enExample) 2021-01-31
TW202011989A (zh) 2020-04-01
JP2021523170A (ja) 2021-09-02
KR20210010486A (ko) 2021-01-27

Similar Documents

Publication Publication Date Title
US20230235060A1 (en) Neutralization of inhibitory pathways in lymphocytes
AU2019270277B9 (en) Treatment of cancer
US20230303691A1 (en) Neutralization of inhibitory pathways in lymphocytes
CN112004828B (zh) 头颈癌的治疗
EA049949B1 (ru) Лечение рака
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
HK40058058A (en) Neutralization of inhibitory pathways in lymphocytes
NZ729207B2 (en) Neutralization of inhibitory pathways in lymphocytes

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)